BUSINESS

Astellas Cuts Costs Ahead of Schedule, Key Assets Entering Late Stages

February 5, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Astellas Pharma said on February 4 that it has achieved significant progress in cost reductions and is accelerating investments in late-stage development programs as it braces for the upcoming patent expiry of Xtandi (enzalutamide), its flagship prostate cancer therapy. At…

To read the full story

Astellas CFO Outlines Cost Cuts, Licensing Push as Xtandi Nears Patent Cliff
August 25, 2025

BUSINESS

Astellas Cuts Costs Ahead of Schedule, Key Assets Entering Late Stages
February 5, 2026
Astellas Lifts Full-Year Forecast, Drops 2 Pipeline Programs
February 5, 2026
3D Says Toho Share Purchase Is Long-Term Investment, Not Attempt at Control
February 5, 2026
MSA Drug NPC-29 Set to Enter PIII This Month: Nobelpharma CEO
February 5, 2026
Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

TSE’s Growth Market Reform Puts Pressure on Biotechs

By Tatsuya Otsuka

Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…